Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results

被引：0
|
作者：
Russo, Filippo [1 ]
Corazzelli, Gaetano [2 ]
Lastoria, Secondo [3 ]
Marcacci, Gianpaolo [2 ]
Frigeri, Ferdinando [2 ]
Capobianco, Gaetana [2 ]
Becchimanzi, Cristina [2 ]
Arcamone, Manuela [2 ]
Pinto, Antonio [2 ]
机构：
[1] IRCSS, Fdn G Pascale, Ist Nazl Tumori, Hematol Oncol & Stem Cell Transplantat Unit, Naples, Italy
[2] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Hematol Oncol & Stem Cell Transplantat Unit, Naples, Italy
[3] IRCCS, Fdn G Pascale, Ist Nazl Tumori, Dept Nucl Med, Naples, Italy
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：298 / 299
页数：2
相关论文
共 37 条
  • [21] Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial
    Gianluca Tomasello
    Wanda Liguigli
    Rossana Poli
    Silvia Lazzarelli
    Matteo Brighenti
    Federica Negri
    Alessandra Curti
    Mario Martinotti
    Lucio Olivetti
    Massimo Rovatti
    Gianvito Donati
    Rodolfo Passalacqua
    Gastric Cancer, 2014, 17 : 711 - 717
  • [22] Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial
    Tomasello, Gianluca
    Liguigli, Wanda
    Poli, Rossana
    Lazzarelli, Silvia
    Brighenti, Matteo
    Negri, Federica
    Curti, Alessandra
    Martinotti, Mario
    Olivetti, Lucio
    Rovatti, Massimo
    Donati, Gianvito
    Passalacqua, Rodolfo
    GASTRIC CANCER, 2014, 17 (04) : 711 - 717
  • [23] Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC).
    Toppo, Laura
    Tomasello, Gianluca
    Liguigli, Wanda
    Lazzarelli, Silvia
    Tanzi, Giulia
    Ghidini, Michele
    Perrucci, Bruno
    Brighenti, Matteo
    Ratti, Margherita
    Panni, Stefano
    Giganti, Maria Olga
    Donini, Maddalena
    Rovatti, Massimo
    Maglietta, Giuseppe
    Ranieri, Valerio
    Grassia, Roberto
    Iiritano, Elena
    Elisa, Iezzi
    Caminiti, Caterina
    Passalacqua, Rodolfo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)
    Toppo, L.
    Tomasello, G.
    Ghidini, M.
    Liguigli, W.
    Lazzarelli, S.
    Caminiti, C.
    Maglietta, G.
    Passalacqua, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Efficacy and safety of dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)
    Toppo, L.
    Tomasello, G.
    Ghidini, M.
    Caminiti, C.
    Maglietta, G.
    Lazzarelli, S.
    Liguigli, W.
    Rovatti, M.
    Ranieri, V.
    Tanzi, G.
    Buffoli, F.
    Martinotti, M.
    Passalacqua, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
    Gobbi, PG
    Levis, A
    Chisesi, T
    Broglia, C
    Vitolo, U
    Stelitano, C
    Pavone, V
    Cavanna, L
    Santini, G
    Merli, F
    Liberati, M
    Baldini, L
    Deliliers, GL
    Angelucci, E
    Bordonaro, R
    Federico, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9198 - 9207
  • [27] BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
    Diehl, V
    Franklin, J
    Hasenclever, D
    Tesch, H
    Pfreundschuh, M
    Lathan, B
    Paulus, U
    Sieber, M
    Rueffer, JU
    Sextro, M
    Engert, A
    Wolf, J
    Hermann, R
    Holmer, L
    Stappert-Jahn, U
    Winnerlein-Trump, E
    Wulf, G
    Krause, S
    Glunz, A
    von Kalle, K
    Bischoff, H
    Haedicke, C
    Duehmke, E
    Georgii, A
    Loeffler, M
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3810 - 3821
  • [28] Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
    Lynch, Ryan C.
    Cassaday, Ryan D.
    Smith, Stephen D.
    Fromm, Jonathan R.
    Cowan, Andrew J.
    Warren, Edus H.
    Shadman, Mazyar
    Shustov, Andrei R.
    Till, Brian G.
    Ujjani, Chaitra S.
    Libby, Edward
    Philip, Mary
    Coye, Hilary
    Martino, Christen N.
    Kanan, Sandra
    Morris, Karolyn K.
    Rasmussen, Heather A.
    Behnia, Sanaz
    Nartea, Margaret E.
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    BLOOD, 2020, 136
  • [29] Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial
    Ferreri, Andres J. M.
    Spina, Michele
    Cattaneo, Chiara
    Verga, Luisa
    Allione, Bernardino
    Ferrari, Daris
    Rigacci, Luigi
    Fumagalli, Luca
    Donadoni, Giovanni
    Lleshi, Arben
    Sassone, Marianna
    Rossi, Giuseppe
    Re, Alessandro
    BLOOD, 2017, 130
  • [30] Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)
    Morris, P. G.
    Dickler, M. N.
    McArthur, H. L.
    Traina, T. A.
    Nulsen, B.
    Steingart, R. M.
    Rugo, S.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
1234